BioStock Executive Bootcamp

Join us on November 11, 2025, for the second annual Executive Bootcamp, a focused afternoon designed for life science founders and C-level executives. This exclusive session offers expert insights, practical advice, and dynamic discussions to prepare you for Big Pharma partnering, learn how to leverage your intellectual property to attract investors, and gain insights into how you can optimise your clinical development strategy for success.

This is a unique opportunity to gain actionable strategies from seasoned industry experts to elevate your company’s growth.
Limited seats available – apply now to secure your spot!

📍 Inspira, Medicon Village, Scheelevägen 4, Lund
🗓️ November 11, 2025
🕐 13:00 to 16:30

This interactive session, hosted in a curated and collaborative environment, offers participants a unique opportunity to engage directly with industry experts. The session will provide an in-depth exploration of the critical stages of deal-making in the biotech sector, offering practical insights and actionable strategies. Attendees will unpack the nuances of business development (BD) and partnering activities, term sheet negotiation, due diligence (DD) processes, deal execution, and post-transaction alliance management.

Through expert-led discussions and Q&A with real-world case examples, participants will gain a comprehensive understanding of the dealmaking process, tailored to entrepreneurs and leaders in the Nordic biotech ecosystem.

The experts leading the session are Jesper Lykkesfeldt, founder and Attorney-at-Law at LYKKESFELDT, with extensive transaction experience from Genmab; Jonathan Sjögren, Search & Evaluation, Respiratory & Immunology, AstraZeneca; Maarit Merla, Managing Director at the Finnish Drug Discovery Center with first-hand sell-side experience of navigating a billion-euro pharma deal; Anu Balendran, Head of Transactions in BD&L, Cardio Renal Metabolism at Novartis; and Bo Skaaning Jensen, Senior Director, Alliance Management at Novo Nordisk.

In this workshop Benjamin Hoffman, Partner and Pattent Attorney at Potter Clarkson, will explore how to leverage your IP strategically to unlock your business’ full potential and maximise its full commercial value.

Attendants will learn how to position their IP to attract investment, maximise exit value and choose and develop exactly the right revenue model. Benjamin will share practical, proven ideas that will explain how IP can drive revenue, attract external financing and put you in the best possible position to reach your goals, whether they are growth, diversification or an exit.

The life science industry is navigating one of its most challenging yet transformative periods. How can biotech leaders build resilience, attract partners, and thrive when capital is tight and timelines are under pressure?

Join TFS HealthScience for a candid, thought-provoking panel offering a CRO-level reality check for the biotech sector. Senior TFS executives will share global insights on market trends, funding shifts, leadership, and culture — exploring how adaptability and smarter collaboration are shaping the next wave of successful biotechs.

Adding an external perspective, Anna Polak Andersen, Head of Clinical Development, Entero Target, contributes her deep experience from the biotech and CRO side — bridging strategy, clinical development, and investor relations.

Panelists include the CEO of TFS Markus Granlund, and CFO  Jesper Hjort, moderated by Hanna Stegared-Pace, Director Business Development at TFS HealthScience.